Stock ARDX ARDELYX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Ardelyx, Inc.

Equities

ARDX

US0396971071

Real-time Estimate Cboe BZX
Other stock markets
 10:45:25 2024-05-14 am EDT 		5-day change 1st Jan Change
7.895 USD -1.56% Intraday chart for Ardelyx, Inc. -15.25% +27.26%
May. 09 Ardelyx Insider Sold Shares Worth $2,522,217, According to a Recent SEC Filing MT
May. 09 Ardelyx Insider Sold Shares Worth $1,831,503, According to a Recent SEC Filing MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ardelyx Insider Sold Shares Worth $2,522,217, According to a Recent SEC Filing
MT
Ardelyx Insider Sold Shares Worth $1,831,503, According to a Recent SEC Filing
MT
Ardelyx Insider Sold Shares Worth $333,574, According to a Recent SEC Filing
MT
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
GL
Ardelyx Shares Rise After Q1 Beat
MT
Wedbush Adjusts Ardelyx's Price Target to $15 From $14, Keeps Outperform Rating
MT
Top Premarket Gainers
MT
Ardelyx: Q1 Earnings Snapshot
AQ
Transcript : Ardelyx, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (ARDX) ARDELYX Reports Q1 Revenue $46M, vs. Street Est of $36.4M
MT
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Ardelyx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
GL
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
AQ
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
GL
Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating
MT
Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target
MT
Ardelyx, Inc. Reports Employment Inducement Grants
GL
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
GL
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARDX Stock
  4. News Ardelyx, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW